Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081
一项随机 II 期研究,旨在评估在不可切除的 IIIA/IIIB 期非小细胞肺癌 (NSCLC) 患者接受同步放化疗后,采用纳武利尤单抗联合伊匹木单抗或单用纳武利尤单抗进行巩固免疫治疗的疗效:十大癌症研究联盟 LUN16-081
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-010316
Durm, Greg; Mamdani, Hirva; Althouse, Sandra; Perkins, Susan; Jabbour, Salma K; Ganti, Apar Kishor; Jalal, Shadia; Chesney, Jason; Naidoo, Jarushka; Hrinczenko, Borys; Fidler, Mary Jo; Leal, Ticiana A; Feldman, Lawrence; Fujioka, Naomi; Hanna, Nasser H